Page last updated: 2024-11-13

5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID20969430
CHEMBL ID1603014
CHEBI ID93464
SCHEMBL ID2718876

Synonyms (19)

Synonym
MLS001030468 -02
MLS001030468
smr000635410
NCGC00187771-01
NCGC00187771-02
ml201
NCGC00187771-04
HMS2245E17
bdbm50398032
chembl1603014 ,
MLS002703121
smr001566926
SCHEMBL2718876
CHEBI:93464
sr-01000146991
SR-01000146991-1
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one
Q27165160
5-[4-(4-acetylphenyl)piperazin-1-yl]sulfonyl-1,3-dihydroindol-2-one

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.56230.044717.8581100.0000AID485294
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency0.98210.036619.637650.1187AID2100; AID2110; AID2111; AID2113; AID2115
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency70.79460.010323.856763.0957AID2662
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency63.09570.050127.073689.1251AID588590
Alpha-synucleinHomo sapiens (human)Potency5.62340.56239.398525.1189AID652106
Guanine nucleotide-binding protein GHomo sapiens (human)Potency7.07951.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysosomal alpha-glucosidaseHomo sapiens (human)IC50 (µMol)0.84500.06002.28897.8000AID705433; AID705434
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysosomal alpha-glucosidaseHomo sapiens (human)INH0.33000.33000.33000.3300AID705436
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (99)

Processvia Protein(s)Taxonomy
maltose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
regulation of the force of heart contractionLysosomal alpha-glucosidaseHomo sapiens (human)
diaphragm contractionLysosomal alpha-glucosidaseHomo sapiens (human)
heart morphogenesisLysosomal alpha-glucosidaseHomo sapiens (human)
glycogen catabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
glucose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
lysosome organizationLysosomal alpha-glucosidaseHomo sapiens (human)
locomotory behaviorLysosomal alpha-glucosidaseHomo sapiens (human)
tissue developmentLysosomal alpha-glucosidaseHomo sapiens (human)
aorta developmentLysosomal alpha-glucosidaseHomo sapiens (human)
vacuolar sequesteringLysosomal alpha-glucosidaseHomo sapiens (human)
muscle cell cellular homeostasisLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling postureLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling balanceLysosomal alpha-glucosidaseHomo sapiens (human)
cardiac muscle contractionLysosomal alpha-glucosidaseHomo sapiens (human)
glycophagyLysosomal alpha-glucosidaseHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
alpha-1,4-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
carbohydrate bindingLysosomal alpha-glucosidaseHomo sapiens (human)
maltose alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
lysosomeLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal membraneLysosomal alpha-glucosidaseHomo sapiens (human)
plasma membraneLysosomal alpha-glucosidaseHomo sapiens (human)
membraneLysosomal alpha-glucosidaseHomo sapiens (human)
azurophil granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal lumenLysosomal alpha-glucosidaseHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal alpha-glucosidaseHomo sapiens (human)
extracellular exosomeLysosomal alpha-glucosidaseHomo sapiens (human)
tertiary granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
ficolin-1-rich granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
autolysosome lumenLysosomal alpha-glucosidaseHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID705431Cytotoxicity in human wild type skin fibroblasts at 10 to 20 uM after 6 days by confocal laser-scanning microscopic analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705414Half life in mouse liver microsomes2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705428Increase in translocation of GAA to lysosomes in human F2845 cells at 1 to 5 uM after 5 days by confocal laser-scanning microscopic analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705436Inhibition of human recombinant GAA assessed as hydrolysis of bovine liver glycogen by Amplex red oxidase assay2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705426Cytotoxicity in human F2845 cells assessed as cell viability at 1 to 5 uM after 5 days confocal laser-scanning microscopic analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705432Binding affinity at wild type recombinant GAA assessed as rise in melting temperature of protein using SYPRO Orange dye by fluorescence assay2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705438Inhibition of alpha-galactosidase2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705433Inhibition of wild type recombinant GAA preincubated for 5 mins measured after 45 mins using red-shifted dye by fluorescence assay2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705417Increase in GAA activity in human wild type skin fibroblasts incubated for 5 days followed by 18 to 40 hrs wash out by fluorescence assay relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705408Efflux ratio from basolateral to apical side to apical to basolateral side of human Caco2 cells2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705424Binding affinity at wild type recombinant NT-495 labelled GAA incubated for 15 mins by microscale thermophoresis assay2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705430Cytotoxicity in human F2845 cells at 10 to 20 uM after 6 days by confocal laser-scanning microscopic analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705435Binding affinity at wild type recombinant GAA assessed as thermostabilization of protein at 50 uM incubated at 66 degC for 60 mins2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705412Permeability from basolateral to apical side of human Caco2 cells2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705434Inhibition of wild type recombinant GAA preincubated for 5 mins measured after 45 mins using blue-shifted dye by fluorescence assay2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705427Cytotoxicity in human wild type skin fibroblasts assessed as cell viability at 1 to 5 uM after 5 days by confocal laser-scanning microscopic analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705407Increase in GAA activity in human wild type skin fibroblasts incubated for 5 days by fluorescence assay relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705429Increase in translocation of GAA to lysosomes in human wild type skin fibroblasts at 1 to 5 uM after 5 days by confocal laser-scanning microscopic analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705406Ratio of Kd for wild type recombinant NT-495 labelled GAA to IC50 for wild type recombinant GAA (unknown origin2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705411Increase in GAA activity in human F2845 cells incubated for 5 days by fluorescence assay relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705416Increase in GAA activity in human F2845 cells incubated for 5 days followed by 18 to 40 hrs wash out by fluorescence assay relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705415Aqueous solubility in PBS buffer2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705437Inhibition of glucocerebrosidase2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID705413Permeability from apical to basolateral side of human Caco2 cells2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Discovery of a novel noniminosugar acid α glucosidase chaperone series.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's6 (66.67)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]